Michael Edward Stewart, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1027 Washington Ave, Detroit Lakes, MN 56501 Phone: 218-847-5611 Fax: 218-847-0881 |
Morris Alan Hund, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1245 Washington Ave., Detroit Lakes, MN 56501 Phone: 218-846-2000 Fax: 218-845-2242 |
Emily Mae Welle, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1027 Washington Ave, Detroit Lakes, MN 56501 Phone: 218-847-5611 |
News Archive
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.
A drug, which reduces insulin resistance and also may have anti-inflammatory and other effects on blood vessels, lowered cardiovascular risk factors in patients with diabetes more than another diabetes medicine, even though both drugs improved blood sugar control equally, according to a new study (PDF) in the June 21, 2005, issue of the Journal of the American College of Cardiology.
MED-EL Medical Electronics, global manufacturer of hearing implant systems and solutions, and CAScination, specialists in surgical navigation solutions and medical robots, have today announced the launch of a revolutionary surgical planning software at the 31st Politzer Society meeting in Gran Canaria.
A protein known to play a role in development and the formation of organs is also an important factor in the control of obesity and diabetes, said researchers from Baylor College of Medicine in a report that appears in the current issue of the journal Cell Metabolism.
Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, today announced it received FDA approval for and is beginning the U.S. launch of the SMARTVIEW remote monitoring solution for patients with implanted cardiac rhythm management devices.
› Verified 8 days ago